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Abstract
Background: To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of
vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer.
Methods: Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases inhibitor) was combined at 100 mg,
200 mg, or 300 mg daily with standard dosed cetuximab and irinotecan (3+3 dose-escalation design). Ten patients were
treated at the MTD and plasma angiogenesis biomarkers (VEGF, PlGF, bFGF, sVEGFR1, sVEGFR2, IL-1b, IL-6, IL-8, TNF-a,
SDF1a) were measured before and after treatment.
Results: Twenty-seven patients were enrolled at 4 dose levels and the MTD. Two dose-limiting toxicities (grade 3 QTc
prolongation and diarrhea) were detected at 300 mg of vandetanib with cetuximab and irinotecan resulting in 200 mg
being the MTD. Seven percent of patients had a partial response, 59% stable disease and 34% progressed. Median
progression-free survival was 3.6 months (95% CI, 3.2–5.6) and median overall survival was 10.5 months (95% CI, 5.1–20.7).
Toxicities were fairly manageable with grade 3 or 4 diarrhea being most prominent (30%). Vandetanib and cetuximab
treatment induced a sustained increase in plasma PlGF and a transient decrease in plasma sVEGFR1, but no changes in
plasma VEGF and sVEGFR2.
Conclusions: Vandetanib can be safely combined with cetuximab and irinotecan for metastatic colorectal cancer.
Exploratory biomarker analyses suggest differential effects on certain plasma biomarkers for VEGFR inhibition when
combined with EGFR blockade and a potential correlation between baseline sVEGFR1 and response. However, while the
primary endpoint was safety, the observed efficacy raises concern for moving forward with this combination.
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Introduction
Colorectal cancer is the fourth most common malignancy and
second most frequent cause of cancer-related death in the United
States, with 141,210 new cases and 49,380 deaths anticipated in
2011. [1] Nineteen percent of patients with colorectal cancer
have metastatic disease at the time of diagnosis [2] and nearly
50% of patients who are initially diagnosed with localized disease
ultimately develop metastases. [3] While there have been
substantive advances in the treatment of metastatic colorectal
cancer over the past decade, [4] median survival for these
patients remains under 2 years in most trials [5] and less than
10% survive for more than 5 years. New treatment strategies
need to be explored.
The two ‘‘biologic’’ therapeutic strategies that have demon-
strated activity in metastatic colorectal cancer target the epidermal
growth factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) both in first and second-line of therapy. [6,7,8]
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proven modest efficacy both as monotherapy and in combination
with chemotherapy in patients with metastatic disease [9,10,11],
receptor tyrosine kinase inhibitors (TKIs) of the EGFR, such as
erlotinib and gefitinib, do not appear to have appreciable activity
against metastatic colorectal cancer as single agents or in
combination with cytotoxic chemotherapy. [12,13,14,15,16] Dual
(antibody + TKI) targeting of EGFR has been shown to overcome
a major drug resistance mutation in mouse models of EGFR
mutant lung cancer. [17] However, whether combined targeting of
the extracellular and intracellular domains of EGFR would be
more efficacious in metastatic colorectal cancer remains not
known. Furthermore, while potential synergistic activity has been
hypothesized for combination of EGFR and VEGFR inhibitors
[18,19,20,21], previous trials have been inconclusive due to lack of
synergy between monoclonal antibodies against VEGF and EGFR
and toxicities seen with such drug combinations and chemother-
apies. [22,23,24].
Vandetanib is an oral multi-targeted antagonist of VEGFR2
and EGFR. [25] In lung cancer, vandetanib was the first TKI with
anti-VEGFR2 activity that significantly prolonged progression-
free survival when combined with chemotherapy in lung cancer.
[26] Thus, combining vandetanib with cetuximab provides an
opportunity to explore the effects of inhibiting both the
extracellular and intracellular domains of EGFR in cancer cells
in conjunction with antiangiogenic/antivascular effects of
VEGFR2 inhibition. To date, KRAS mutation status remains
the only biomarker used for cetuximab treatment, and there are
no validated biomarkers of anti-VEGF therapies. [27] Here, we
conducted a multi-center phase I study to assess the safety of
combining cetuximab, irinotecan and vandetanib and explore
efficacy and biomarkers for the treatment of previously treated
metastatic colorectal cancer patients.
Methods
Patients
Patients were eligible if they had metastatic colorectal adeno-
carcinoma and had received 1–2 prior chemotherapy regimens for
metastatic disease (prior adjuvant therapy completed within 12
months of enrollment was considered 1 prior regimen). At study
onset (February 2007), data on treatment interaction between
KRAS mutation status and cetuximab was not known and thus the
first 7 patients were not selected by KRAS status; the protocol was
amended on July 17, 2008 to restrict to only patients with KRAS
wildtype tumors. Patients had to have measurable disease by
Response Evaluation Criteria in Solid Tumors Group (RECIST),
[28] an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0–2, and adequate hematological, hepatic and renal
function. Patients could not have been previously treated with
prior EGFR inhibitor (prior irinotecan was permitted). Exclusion
criteria included uncontrolled serious medical or psychiatric
illness, other malignancy within past 3 years (except limited basal
cell or squamous cell carcinoma of the skin or in situ cervix
carcinoma), inadequately controlled hypertension (blood pressure
.160/100 mmHg on antihypertensive medications), clinically
significant cardiac event such as myocardial infarction or New
York Heart Association classification of heart disease .2 within 3
months of study entry, history of ventricular arrhythmia that was
either symptomatic or required treatment, potassium ,4.0 mEq/
L despite supplementation, serum calcium (ionized or adjusted for
albumin) or magnesium out of normal range despite supplemen-
tation, previous history of QTc prolongation as a result from other
medication that required discontinuation of that medication,
congenital long QT syndrome, first degree relative with unex-
plained sudden death under 40 years of age, presence of left
bundle branch block, QTc with Bazett’s correction that is
unmeasurable or $480 msec on ECG, concomitant medication
that may cause QTc prolongation induced Torsades de Pointes or
induce CYP3A4 function, lack of physical integrity of the upper
gastrointestinal tract or malabsorption syndrome, currently active
diarrhea that may affect ability to absorb vandetanib or tolerate
potential diarrhea from study drugs, pregnancy or active lactation,
and incompletely healed surgical incisions.
Patients were accrued from Brigham and Women’s Hospital,
Massachusetts General Hospital and Beth Israel Deaconess
Medical Center in Boston. The study was approved by the
Dana-Farber/Harvard Cancer Center Institutional Review Board
which oversees studies at all three hospitals. All patients signed
informed consent.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Treatment
This was a phase I trial with an expanded maximum tolerated
dose (MTD) cohort. Throughout the study, standard dosing of
cetuximab was utilized (400 mg/m
2 loading dose followed by
weekly 250 mg/m
2 doses). Dose level 1 was without irinotecan
(vandetanib and cetuximab only); all subsequent dose levels
included irinotecan starting on day 15 of therapy at 180 mg/m
2
intravenously every other week. Dose levels 2, 3, and 4 including
oral vandetanib daily at 100 mg, 200 mg and 300 mg, respec-
tively, with cetuximab and irinotecan. Patients were enrolled into
each dose level initially in cohorts of 3. No intrapatient dose
escalation was permitted. If all 3 patients treated at a dose level
were observed during cycle 1 without dose-limiting toxicity, then a
new cohort of 3 patients received the next dose level. If 2 of the
initial 3 patients experienced a dose-limiting toxicity (DLT), then
the previous dose was considered the MTD. If a DLT was
observed in one of the initial 3 patients, then 3 additional patients
were treated at that dose level. If none of those 3 additional
patients experienced a DLT, then the next dose level was
administered; otherwise, the previous dose was considered the
MTD. Ten additional patients were treated at the MTD. DLTs
were defined as specific toxicities observed in the first 28 days of
dose level 1 and the first 35 days of dose levels 2–4 (due to the
delayed introduction of irinotecan). The DLTs included grade IV
hematological toxicity .7 days, fever and neutropenia, grade III
diarrhea leading to hospitalization or lasting .48 hours despite
aggressive anti-diarrheal medication, grade IV diarrhea despite
aggressive anti-diarrheal medication, grade IV vomiting despite
optimal antiemetics, grade III or higher nonhematological toxicity
(excluding nausea, vomiting, diarrhea, or alopecia) lasting .1
week, grade 4 skin toxicity, grade 3 or greater cardiac toxicities or
death from any cause.
All toxicities were graded according to the National Cancer
Institute (NCI) Common Toxicity Criteria (CTC) version 3.0.
Dose reductions for vandetanib depended on starting dosage, with
initially 100 mg per day reductions and finally reduction from
100 mg daily to every other day. If further reductions were
needed, patient was withdrawn from the study. Due to concerns
regarding QTc prolongation with vandetanib, initially frequent
EKGs were performed and vandetanib was held for patients with
either a single QTc value of 550 msec or greater, single QTc
increase of 100 msec or greater from baseline, or two consecutive
EKG measurements within 48 hours of one another in which the
mean QTc interval from 3 EKGs is greater than 500 but less than
Vandetanib in Metastatic Colorectal Cancer
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greater than 60 but less than 100. Upon treatment hold, efforts
were made to replete appropriate electrolytes and treatment
resumed once QTc resolved to within 60 msec of baseline at a
dose reduction. Further increases of QTc required removal of the
patient from the study. Vandetanib was held for grade 3 or 4
cutaneous reactions as well as other grade 3 or 4 toxicities deemed
associated with the study medication, with resumption once
resolved to grade 1 or less toxicity with a dose reduction.
Vandetanib could be held for up to 3 weeks.
Cetuximab and irinotecan dose modifications were consistent
with other protocols [9,29] and their individual package labels.
Treatment was continued until development of progressive
disease by RECIST, unacceptable toxicity, withdrawal of consent,
intercurrent illness that prevented continuation of therapy, or
changes in the patient’s condition that rendered him or her unable
to continue study drugs (as judged by the treating clinician).
Response Evaluation
Baseline tumor measurements by computer tomography were
obtained within 28 days before treatment was initiated. Treatment
cycles were defined at every 8 weeks. Study visits included toxicity
assessment, physical examination, and laboratory studies were
conducted weekly during cycle 1 and then every other week for
subsequent cycles. Patients were asked to keep a diary of their self-
administration of vandetanib as well as record daily side effects;
these diaries were reviewed at each study visit. EKGs were
obtained at baseline, weeks 1, 2, 4, 8 and then day 1 of every
subsequent cycle.
Repeat imaging was required prior to start of each cycle.
Evaluation of response, stable disease and disease progression was
based on RECIST. [28] Confirmation scans for responders were
performed at least 4 weeks after the initial scan documenting the
reduction.
Biomarker Studies
Exploratory biomarker studies were conducted in the 10 patients
treated at the MTD. Blood samples were collected prior to first
dose of any therapy on day 1 then on days 8, 15, 22 of cycle 1 then
on day 1 of every subsequent cycle. Circulating angiogenic and
inflammatory biomarkers were measured in plasma. Analysis was
carried out for circulating VEGF, placental growth factor (PlGF),
soluble VEGF receptor 1 (sVEGFR1), basic fibroblast growth
factor (bFGF), interleukin (IL)-1b, IL-6, IL-8, tumor necrosis factor
a (TNFa) using multiplex enzyme-linked immunosorbent assay
(ELISA) plates from Meso-Scale Discovery (Gaithersburg, MD).
sVEGFR2 and stromal cell–derived factor 1a (SDF1a) were
similarly analyzed using ELISA plates from R&D System
(Minneapolis, MN). Every sample was run in duplicate.
Statistical Analysis
The primary endpoint of this study was to determine the
tolerability and maximum tolerated dose of combining vandetanib,
cetuximab and irinotecan in patients with metastatic colorectal
cancer refractory to prior cytotoxic chemotherapy. Secondary
endpoints were determinations of response rate, progression-free
survival and overall survival of this combination. Responses were
determined by RECIST with an intention-to-treat analysis. [28]
Progression-free survival (PFS) was defined as the time between
study enrollment and progression of disease or death. Overall
survival (OS) was defined as the time between study enrollment and
death and estimated by the Kaplan-Meier method. [30].
Figure 1. Study CONSORT Flow Diagram.
doi:10.1371/journal.pone.0038231.g001
Table 1. Baseline characteristics (n=27).
Characteristic Distribution
Age (years)
Median 53
Range 31–74
Gender
Female 13 (48%)
Male 14 (52%)
Race
Caucasian 24 (89%)
Other 3 (11%)
Baseline ECOG Performance Status
0 12 (44%)
1–2 15 (56%)
Prior lines of therapy (including prior adjuvant therapy)
1 15 (56%)
2 10 (37%)
3 2 (7%)
Prior irinotecan-based therapy 15 (56%)
Prior oxaliplatin-based therapy (adjuvant or metastatic or
both)
22 (81%)
Site of primary tumor
Colon 21 (78%)
Rectum 6 (22%)
doi:10.1371/journal.pone.0038231.t001
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interquartile range and the P-values were determined using the
paired exact Wilcoxon test. We adjusted P values for multiple
comparisons over time, using the false discovery rate control
method of Genovese and colleagues [31], with weights proportional
to the square root of the number of data. Kendall’s nonparametric
coefficients of correlation tb and the two-sided Kendall’s test were
used to quantify the correlation of biomarkers with tumor relative
size change and RECIST criteria and to test tb=0.
Results
Patient Characteristics
Twenty-seven patients enrolled into this phase I study of
vandetanib in combination with irinotecan and cetuximab from
March 2007 to March 2010 (Figure 1). Baseline characteristics of
these patients are summarized in Table 1. The median age of the
patients was 53, 52% were male, and 11% were race other than
Caucasian. Over half of all patients had a baseline ECOG
performance status of 1 or 2 and 44% had received 2 or more
prior therapies for metastatic colorectal cancer.
Determination of the Maximum Tolerated Dose
Four patients were enrolled at dose level 1 (vandetanib 100 mg
per day with cetuximab) without a DLT (one patient was added
due to symptomatic disease progression prior to 28 day required
period for DLT detection in one of the first 3 patients). Dose levels
2 and 3 added irinotecan to cetuximab and vandetanib (100 mg
per day and 200 mg per day, respectively) and no DLTs were
Table 2. Adverse Events (based on worse toxicity by patient).
Dose Level 1
N=4
Dose Level 2
N=3
Dose Level (MTD)
N=15
Dose Level 4
N=5
Toxicity
Grade 1/2
n( % )
Grade 3/4
n( % )
Grade 1/2
n( % )
Grade 3/4
n( % )
Grade 1/2
n( % )
Grade 3/4
n( % )
Grade 1/2
n( % )
Grade 3/4
n( % )
Rash 4 (100%) – 3 (100%) – 13 (87%) 2 (13%) 4 (80%) 1 (20%)
Electrolyte changes* 4 (100%) – 2 (67%) 1 (33%) 9 (69%) 3 (20%) 3 (60%) 1 (20%)
Fatigue 4 (100%) – 3 (100%) – 10 (67%) – 4 (80%) –
Dry skin/Pruritus 1 (25%) – 1 (33%) – 6 (40%) 1 (7%) 4 (80%) –
Diarrhea 1 (25%) – 2 (67%) 1 (33%) 11 (73%) 4 (27%) 2 (40%) 3 (60%)
Nausea 1 (25%) – 1 (33%) – 6 (40%) – 3 (60%) –
Emesis 1 (25%) – 2 (67%) – 4 (27%) – 3 (60%) –
Anorexia 2 (50%) – 1 (33%) – 3 (20%) – 4 (80%) –
Liver function changes 1 (25%) – 2 (67%) – 6 (40%) 1 (7%) 3 (60%) 1 (20%)
Neutropenia – – 1 (33%) 1 (33%) – 1 (7%) – 1 (20%)
Lymphopenia 1 (25) – 3 (100%) – 4 (27%) – 2 (40%) –
Anemia – – 1 (33%) – 3 (20%) – 1 (20%) –
Thrombocytopenia – – – – 2 (13%) – 1 (20%) –
Headache 1 (25%) – 3 (100%) – 2 (13%) – 2 (40%) –
Nail changes – – 1 (33%) – 4 (27%) – 2 (40%) –
Dehydration – – – – 3 (20%) – 2 (40%) –
Constipation – – 1 (33%) – 3 (20%) – 2 (40%) –
Abdominal pain 2 – 1 (33%) 1 (33%) 1 (7%) – 2 (40%) –
Other pain 1 (25%) – 1 (33%) 1 (33%) 1 (7%) – 2 (40%) –
Shortness of breath 2 (50%) – – 1 (33%) 2 (13%) – – –
Fever without neutropenia 1 (25%) – 1 (33%) – 2 (13%) – – –
Creatinine elevation 1 (33%) – – 1 (7%) 1 (20%) –
Toxicity Dose Level 1
N=4
Dose Level 2
N=3
Dose Level 3/MTD
N=15
Dose Level 4
N=5
Ocular irritation 1 (25%) – – – 1 (7%) – – –
QTc prolongation – – – – – – – 1 (20%)
Hypertension – – – – – 1 (7%) 1 (20%) –
Proteinuria – – – – 2 (13%) – 1 (20%) –
Neuropathy – – – – 2 (13%) – – –
Alopecia – – – – 2 (13%) 1 (7%) – –
Any grade 3 or 4 – – – 2 (67%) – 8 (53%) – 5 (100%)
*includes magnesium, potassium, sodium and calcium changes.
doi:10.1371/journal.pone.0038231.t002
Vandetanib in Metastatic Colorectal Cancer
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38231detected. Three patients were enrolled at dose level 2 and 5 were
enrolled at dose level 3 because 1 patient had symptomatic
progression within the DLT monitoring period and 2 patients
were consented simultaneously. At dose level 4 (i.e., vandetanib
300 mg per day with cetuximab and irinotecan), one of the initial
3 patients experienced a DLT (grade 3 QTc prolongation). The
dose level 4 cohort was expanded to an additional 3 patients
however the second patient experienced a DLT (grade 3 diarrhea).
Therefore, dose level 4 was considered too toxic and MTD was
determined to be vandetanib 200 mg per day, irinotecan 180 mg/
m
2 intravenously every other week and cetuximab 400 mg/m
2
loading dose followed by weekly cetuximab 250 mg/m
2. Ten
additional patients were treated at the MTD.
Toxicity
Twenty-seven patients were evaluated for treatment-associated
toxicities, by dose level of treatment (Table 2). While dose level 4
was discontinued due to two patients experiencing protocol
defined DLTs, overall toxicities appeared greater by percentage
compared to the other dose levels as well. In considering the entire
cohort, all patients developed some level of a rash, with 11% being
classified as grade 3. Electrolyte changes were also very common
(85% of patients) though only 5 patients (19%) experienced grade
3 or 4 abnormalities, 4 with hypomagnesium and 1 with
hypokalemia. Fatigue was seen in 78% of patients, though all
were classified as grade 1 or 2.
Any grade 3 or 4 toxicity was observed in 59% of patients, with
all patients in dose level 4 experiencing at least one. Besides
electrolyte abnormalities and rash, 8 patients (30%) had grade 3 or
4 diarrhea, 3 patients (11%) had grade 3 neutropenia, 1 patient
had grade 3 and 1 patient had grade 4 liver function
abnormalities. Other grade 3 toxicities experienced by a single
patient included pruritus, abdominal pain, shortness of breath,
creatinine elevation, ocular irritation, QTc prolongation, hyper-
tension, and alopecia.
Efficacy and Duration of Treatment
Among the 27 patients enrolled in this phase I trial of
vandetanib, cetuximab and irinotecan, 24 patients were evaluable
for radiographic response (3 were removed from study due to
toxicity prior to restaging scans). Amongst the 24 patients, 12.5%
had a partial response, 62.5% had stable disease and 25% had
progressive disease as best response (Figure 2). The median PFS
for the entire cohort of 27 patients was 3.6 months (95%
confidence interval [CI], 2.2–5.6) and median OS was 9.2 months
(95% CI, 4.8–17.4) (Figure 3). When considering only the 20
patients known to be KRAS wild type, median PFS was 3.7
months (95% CI, 2.2–5.7) and median OS 9.8 months (95% CI,
4.0–21.0). When analyses are limited to only the 15 patients
treated at the MTD (including those treated at those doses during
dose determination phase), the median PFS was 5.6 months (95%
CI, 1.8–6.4) and median OS 15.5 months (95% CI, 3.2–27.3).
Figure 2. Waterfall Plot. Best response analysis after vandetanib with cetuximab and irinotecan limited to patients with confirmed KRAS wild-type
metastatic colorectal cancer and at least 1 restaging imaging scan.
doi:10.1371/journal.pone.0038231.g002
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due to progression of disease. Ten patients (37%) stopped therapy
due to toxicity. One patient who experienced stable disease as best
response underwent curative-intent surgery for liver metastases.
Finally, one patient withdrew consent due to need for Achilles
tendon surgery.
Exploratory Analyses of Plasma Biomarkers
Vandetanib and cetuximab treatment increased the plasma
concentration of plasma PlGF and decreased sVEGFR1 (p,0.05)
(Table 3). The increase in plasma PlGF was maintained after
irinotecan was added to vandetanib and cetuximab. In contrast,
plasma sVEGFR2, VEGF, bFGF, SDF1a, IL-1b, IL-6, IL-8 and
TNF- a were not significantly changed in this cohort after
vandetanib and cetuximab nor after addition of irinotecan in these
patients. Of all biomarkers, baseline (pre-treatment) sVEGFR1
correlated inversely with response assessed by RECIST (p,0.05).
Discussion
In this phase I study of patients with previously treated
metastatic colorectal cancer, we determined that oral vandetanib
at 200 mg daily could be safely combined with weekly cetuximab
and every other week irinotecan. As defined by the protocol a
priori, diarrhea and QTc interval prolongation were DLTs at a
higher dose of vandetanib. However, the activity of the regimen at
the MTD was rather modest and not appreciably different from
historical data for cetuximab and irinotecan in KRAS wild-type
patients.
The landscape of treatment for colorectal cancer had changed
at a rapid pace since 1998 and 2006. Prior to 1998, the only drug
approved was 5-fluorouracil. However, in the span of less than a
decade, two additional cytotoxic chemotherapies (irinotecan and
oxaliplatin), two inhibitors of EGFR (cetuximab and panitunu-
mab) and one monoclonal antibody against VEGF (bevacizumab)
have demonstrated efficacy in randomized phase III trials and are
being routinely incorporated into regimens to treat metastatic
colorectal cancer. Despite improvements in median survival from
less than 1 year to greater than 2 years in this time period, most
patients with metastatic colorectal cancer will still eventually die
from their disease. Many efforts are currently underway to target
new pathways important to the growth and metastatic potential of
colorectal cancer.
Figure 3. Kaplan-Meier Curves of Progression-Free Survival (PFS) and Overall Survival (OS) Distributions after Vandetanib with
Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients. A, PFS distribution for all patients (n=27). B, PFS distribution for
patients with confirmed KRAS wild-type tumors (n=20). C, PFS distribution for all patients (n=27). D, PFS distribution for patients with confirmed
KRAS wild-type tumors (n=20).
doi:10.1371/journal.pone.0038231.g003
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cancer is to further capitalize on the pathways that have had some
therapeutic potential in this disease, EGFR and VEGFR.
Cetuximab and panitumumab target the extracellular domain of
EGFR, blocking ligand binding. Preclinical experiments support
combining EGFR monoclonal antibodies with oral inhibitors of
EGFR tyrosine kinase, with synergistic effects on proliferation and
induction of apoptosis as well as enhancement of phosphorylation
inhibition of downstream effector molecules (e.g., MAPK and
AKT). [32,33] Vandetanib is receptor tyrosine kinase inhibitor
with inhibitory activity against EGFR (IC50=500 nM) tyrosine
kinase. [34,35] In addition, vandetanib inhibits vascular endothe-
lial growth factor receptor-2 (VEGFR-2) (VEGFR-2:
IC50=40 nM) and Rearranged during Transfection (RET:
IC50=100 nM) tyrosine kinase activity. [36,37] Vandetanib has
been recently approved for advanced medullary thyroid cancer, a
disease driven by activating mutations in the RET proto-oncogene
[38], but has also shown activity with chemotherapy in lung
Table 3. Pre-treatment values and fold-changes in plasma biomarkers after treatment with vandetanib and cetuximab (days 8 and
15) and with vandetanib, cetuximab and irinotecan (day 21, cycle 3 and cycle 5) in metastatic colorectal cancer patients.
Biomarker Pre-treatment Day 8 Day 15 Day 21 Cycle 3 Cycle 5
VEGF 878 pg/ml [485,1559] (n=8) 0.92 [0.86,1.05]
(n=7)
0.86 [0.81,0.97]
(n=8)
0.67 [0.57,0.74]
(n=8)
0.41 [0.23,0.67]
(n=7)
1.27 [0.86,1.05]
(n=4)
P 0.69 0.11 0.016 0.47 0.88
Adjusted P 0.86 0.18 0.078 0.12 0.88
PlGF 37 pg/ml [29,44] (n=8) 1.36 [1.32, 1.46]
(n=7)
1.34 [1.09, 1.50]
(n=8)
1.60 [1.44, 1.87]
(n=8)
1.64 [1.06, 1.68]
(n=7)
1.44 [1.24, 1.81]
(n=4)
P 0.016 0.016 0.0078 0.078 0.13
Adjusted P 0.026 0.026 0.026 0.098 0.13
sVEGFR1 470 pg/ml [277,677] (n=8) 0.70 [0.65,1.04]
(n=7)
0.49 [0.41,0.57]
(n=8)
0.60 [0.17,0.83]
(n=8)
0.85 [0.35,1.08]
(n=7)
0.29 [0.21,0.47]
(n=4)
P 0.22 0.0078 0.039 0.30 0.13
Adjusted P 0.27 0.039 0.098 0.30 0.21
sVEGFR2 5,040 pg/ml [4,490, 7,030] (n=8) 1.02 [0.99,1.15]
(n=7)
0.95 [0.91,1.12]
(n=8)
0.93 [0.91,1.04]
(n=8)
0.93 [0.83,1.04]
(n=7)
0.84 [0.78,0.90]
(n=4)
P 0.37 0.95 0.31 0.30 0.25
Adjusted P 0.47 0.95 0.47 0.47 0.47
bFGF 40.7 pg/ml [24.2,151.9] (n=8) 1.09 [0.70, 4.06]
(n=7)
1.70 [0.78, 2.20]
(n=8)
1.35 [0.66, 5.07]
(n=8)
3.66 [0.69, 6.53]
(n=7)
3.12 [1.98, 6.33]
(n=4)
P 0.81 0.64 0.46 0.47 0.25
Adjusted P 0.81 0.80 0.78 0.78 0.78
SDF1a 2,532 pg/ml [2,380, 3,304] (n=8) 1.12 [0.97, 1.25]
(n=7)
1.07 [0.89, 1.24]
(n=8)
1.05 [0.94, 1.28]
(n=8)
1.18 [0.86, 1.23]
(n=7)
0.99 [0.81, 1.25]
(n=4)
P 0.58 0.95 0.55 0.69 1.0
Adjusted P 1.0 1.0 1.0 1.0 1.0
IL-1b 0.60 pg/ml [0.40,0.85] (n=8) 1.00 [0.83, 1.82]
(n=7)
1.05 [0.62, 1.52]
(n=8)
0.96 [0.56, 1.62]
(n=8)
1.43 [0.92, 1.93]
(n=7)
0.67 [0.46, 0.99]
(n=4)
P 0.44 0.81 0.95 0.30 0.38
Adjusted P 0.73 0.95 0.95 0.73 0.73
IL-6 3.70 pg/ml [2.70,5.32] (n=8) 1.19 [0.84, 1.68]
(n=7)
1.60 [1.06, 2.34]
(n=8)
1.78 [1.36, 3.25]
(n=8)
2.07 [1. 23, 3.80]
(n=7)
0.99 [0.71, 1.25]
(n=4)
P 0.38 0.20 0.25 0.30 0.88
Adjusted P 0.47 0.47 0.47 0.47 0.88
IL-8 15.82 pg/ml [8.65,31.49] (n=8) 0.81 [0.38,0.86]
(n=7)
0.80 [0.58,1.02]
(n=8)
0.99 [0.70,1.28]
(n=8)
0.81 [0.62,1.16]
(n=7)
0.47 [0.40, 1.03]
(n=4)
P 0.22 0.31 0.95 0.69 0.63
Adjusted P 0.27 0.86 0.95 0.86 0.86
TNF-a 11.9 [10.2,14.4] (n=8) 1.14 [0.95, 1.47]
(n=7)
1.11 [0.90, 1.38]
(n=8)
0.95 [0.64, 1.23]
(n=8)
1.04 [0.84, 1.39]
(n=7)
0.72 [0.63, 0.95]
(n=4)
P 0.47 0.38 0.64 0.69 0.38
Adjusted P 0.69 0.69 0.69 0.69 0.69
Data are shown as medians and interquartile ranges (in square brackets) compared to baseline levels. P-values are from the exact paired Wilcoxon test, before and after
adjustment for multiple comparisons over time using the method of Genovese at al. VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; PlGF,
placental growth factor; sVEGFR-1, soluble VEGF receptor-1; sVEGFR-2, soluble VEGF receptor-2; SDF-1a, stromal cell-derived factor-1-alpha; IL-6, interleukin-6; IL-8,
interleukin-8; TNF-a, tumor necrosis factor-alpha.
doi:10.1371/journal.pone.0038231.t003
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inhibition. [26] This supported the rationale for testing vandetanib
with cetuximab as a unique strategy to dual targeting of EGFR
extracellular and intracellular domains as well as combined EGFR
and VEGFR2 inhibition.
This phase I trial of vandetanib, cetuximab and irinotecan was
initiated prior to the discovery of KRAS status as marker of
cetuximab activity. [39] The protocol was amended after the first
seven patients to limit to those most likely to benefit from
cetuximab and irinotecan. The anticipated benefit of cetuximab
and irinotecan in second-line metastatic colorectal cancer is
median PFS of 5–5.5 months and median OS of 11 months, based
on retrospective data from a large cohort of 448 patients with
previously treated, KRAS wildtype, metastatic colorectal cancer
treated with cetuximab plus chemotherapy. [40] While the sample
size in this current trial limits tight confidence intervals around the
efficacy endpoints, there does not appear to be appreciable
improvement in PFS or OS with this combination.
The lack of efficacy for this strategy raises two issues that have
become increasingly apparent in other studies of VEGF and
EGFR inhibitors. First, unlike antibodies, using TKIs for targeting
EGFR (e.g., gefitinib or erlotinib) or VEGFR (e.g., vatalanib,
sunitinib, sorafenib and cediranib) has shown disappointing results
in trials of TKI combined with chemotherapy for metastatic
colorectal cancer; [12,13,14,23,41,42,43,44,45,46,47] similarly, all
phase III trials of single agent TKI have failed with the exception
of one trial utilizing regorafenib in latter line therapy.
[15,16,45,48] The biological rationale of the limited activity of
these small molecular inhibitors compared to monoclonal
antibodies against the same receptor is not clear. Second,
combination trials of cetuximab or panitumumab with bevacizu-
mab have also led to disappointing and concerning results, at least
when tested in first-line therapy. [22,24] Our results using an
antibody and a TKI for EGFR and VEGF inhibition supports the
lack of efficacy of dual targeting of these pathways in KRAS wild-
type metastatic colorectal cancer as opposed to an unknown
interaction between monoclonal antibodies.
These underwhelming data notwithstanding, there is an
increasing realization that targeted therapies, as well as cytotoxic
treatments, will likely only benefit subgroups of patients with a
given cancer. Molecular markers are hoped to provide a means to
better assess upfront to choose a therapy for a particular patient or
to allow for a very early assessment of whether a treatment has
potential to benefit. To date, KRAS status is the only predictive
biomarker that defines the utility of treatment choice in colorectal
cancer: mutant KRAS patients are excluded from cetuximab
treatment. [39] In this trial, we explored plasma markers of
angiogenesis and inflammation as markers of activity as well as
assessments of whether the therapy was impacted on the assumed
molecular process. Consistent with the anti-VEGF activity of
vandetanib–and in agreement with data from trials of other VEGF
inhibitors in colorectal carcinoma patients (e.g., bevacizumab)–
treatment increased the plasma concentration of plasma PlGF and
decreased sVEGFR1. [27,49] The probability of a response
increased significantly with lower plasma levels of sVEGFR1 at
baseline. Of note, this inverse correlation between pretreatment
sVEGFR1 (an endogenous inhibitor of VEGF and PlGF) and
outcome has been previously seen in patients with rectal cancer
after bevacizumab and chemoradiation [27,50] as well as after
bevacizumab with chemotherapy in breast cancer and cediranib in
hepatocellular carcinoma (Sara Tolaney and Andrew Zhu,
personal communication). Plasma sVEGFR-2 concentration has
been previously proposed as a ‘‘pharmacodynamic biomarker’’ for
multiple agents with anti-VEGFR-2 TKI activity when used as
monotherapy. [27] Surprisingly, vandetanib did not decrease
plasma sVEGFR2 in this cohort. This result may be explained by
the relatively weak anti-VEGFR-2 TKI activity of vandetanib
[51,52] or by its use in combination with cetuximab and
chemotherapy. Similarly, most anti-VEGF agents increase plasma
VEGF levels, [27] including vandetanib in lung cancer patients,
[51] while EGFR inhibition is thought to decrease VEGF
expression by cancer cells. [53] In this trial, we found a trend
toward decreased plasma VEGF after vandetanib, cetuximab and
irinotecan treatment. While exploratory, these results suggest that
circulating sVEGR1 should be further tested as a predictive
biomarker candidate and PlGF should be further tested as a
selective and specific pharmacodynamic biomarker candidate for
other anti-VEGF therapies. On the other hand, the level of
circulating inflammatory cytokines did not change after treatment.
Taken together, the biomarker kinetics suggest that despite
minimal anti-tumor activity, vandetanib and cetuximab may
adequately suppress target (EGFR and VEGFR2) activity in
metastatic colorectal cancer.
In conclusion, vandetanib can be safely combined with
cetuximab and irinotecan. However, while the primary objective
of the study was evaluation of safety of the combination, there is no
apparent increase in efficacy of this combination compared to
historic data in previously treated metastatic colorectal cancer
patients. [6,54] Despite the apparent lack of improved efficacy,
our plasma biomarker data suggest that the anticipated targets
may have been impacted, and could potentially benefit a subset of
patients. This suggests that future studies should examine specific
mechanism escape for EGFR and VEGFR inhibition to design
biology-driven approaches for improved therapy in metastatic
colorectal cancer.
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